<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2997">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601077</url>
  </required_header>
  <id_info>
    <org_study_id>IND150758 Pilot</org_study_id>
    <nct_id>NCT04601077</nct_id>
  </id_info>
  <brief_title>The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans</brief_title>
  <official_title>Pilot Study: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric Oxide Innovations LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric Oxide Innovations LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, double blinded, prospective, placebo controlled&#xD;
      study. Patients upon diagnosis of COVID-19 (Corona Virus Disease-19) will be eligible to&#xD;
      participate in the study. The purpose of this study is to find out the side effects and&#xD;
      ability to take the study drug, Nitric Oxide (NO) lozenges when taken twice daily by mouth.&#xD;
      If this study shows that the drug has no or few, acceptable side effects, it will then&#xD;
      include up to 840 participants to find out if the drug can reduce bad outcomes of COVID-19&#xD;
      infection (hospitalization, ICU admission, death). In each part of the study, half of the&#xD;
      subjects will receive the study drug and the other half will be given a placebo (inactive&#xD;
      pill).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo Control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low blood pressure</measure>
    <time_frame>30 days</time_frame>
    <description>Blood pressure under 90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dizziness</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of self reported dizziness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization, ICU admission, intubation, dialysis and death</measure>
    <time_frame>30 Days</time_frame>
    <description>The effects of NO therapy on incidence of hospitalization, intubation, ICU admission, dialysis and death in treated patients vs. those receiving placebo therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Nitric Oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide lozenges, 30 mg</intervention_name>
    <description>Nitric Oxide lozenge, 30 mg twice a day for 30 days</description>
    <arm_group_label>Nitric Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of 50-85 years of age&#xD;
&#xD;
          2. Subjects with recent COVID-19 diagnosis (within 72 hours), that are symptomatic&#xD;
             (fever, cough, SOB, weakness, or other flu-like symptoms).&#xD;
&#xD;
          3. Agrees to comply with study procedures (diary, oximeter readings, telephone follow&#xD;
             up).&#xD;
&#xD;
          4. Has given voluntary, written, informed consent to participate in the study.&#xD;
&#xD;
          5. Identifies as African American.&#xD;
&#xD;
          6. Patients must have at least 1 risk factor (history of hypertension (BP&gt; 140/99) CHF,&#xD;
             angina, prior MI, coronary angiography with one significantly occluded vessel,&#xD;
             diabetes mellitus, obesity, or smoking, (for at least 5 years).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, breastfeeding or planning to become pregnant during the&#xD;
             course of the study.&#xD;
&#xD;
          2. Patients unresponsive or unable to take anything by mouth (NPO).&#xD;
&#xD;
          3. Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent.&#xD;
&#xD;
          4. Blood pressure below 110 mmHg systolic and 60 mmHg diastolic on entry into study.&#xD;
&#xD;
          5. History of syncope or other symptoms of orthostatic hypotension.&#xD;
&#xD;
          6. History of methemoglobinemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-representation</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John C Somberg, MD</last_name>
    <phone>847-735-1170</phone>
    <email>johnsomberg@comcast.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>American Institute of Therapeutics</name>
      <address>
        <city>Lake Bluff</city>
        <state>Illinois</state>
        <zip>60044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John C Somberg, MD</last_name>
      <phone>847-735-1170</phone>
      <email>johnsomberg@comcast.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

